Otosclerosis
Conditions
Keywords
otosclerosis, inner ear, tiludronic acid
Brief summary
The aim of this study is to assess the efficacy of a biphosphonate (tiludronic acid, Skelid®, Sanofi-Aventis) in the treatment of inner ear involvement in advanced otosclerosis
Detailed description
Otosclerosis is a bone dystrophy localized to middle and inner ears with unknown etiology. It principally concerns adult patients between 30 and 50 years of age. Women present with this disease 2 times more frequently than men. Family cases are observed in 50% with a dominant autosomal transmission and low penetrance (40%). In its early stages, the disease is mainly located at the stapediovestibular joint leading to its ankylosis and a conductive hearing loss. In its advanced stages, the lesions extend around the cochlea and vestibule, induce a sensorineural hearing loss which can progress to severe and profound deafness, and prolonged balance disorders. On CT-scan, disease foci show a demineralization. Their density is inversely correlated to the hearing loss. In early stage, hearing function is currently rehabilitated by conventional hearing aids or surgery. In advanced forms, cochlear involvement is not accessible to surgery, and rehabilitation is insured by he hearing aids or cochlear implants. Vestibular dysfunction is dealt with by physiotherapy or symptomatic treatment. Drugs with anabolic activity in bone, such as sodium fluoride and etidronate (first generation bisphosphonate, Didronel ®), appear to reduce the hearing loss and to increase the radiological density of disease foci. However, their efficacy is low and poorly documented. Their effect on vestibular function is unknown. Moreover, ototoxicity has been reported for etidronate. New biphosphonates such as tiludronic acid (Skelid ®) have a significantly more potent inhibition of bone resorption and do not have an ototoxic effect. They have been used for the treatment or the prevention of postmenopausal osteoporosis and in Paget's disease with mild to moderate adverse effects in the majority of cases.
Interventions
DRUGtiludronic acid
400 mg / day for 3 months
DRUGPlacebo
400 mg / day for 3 month
Sponsors
Assistance Publique - Hôpitaux de Paris
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age between 18 and 75 years * French citizen * Signed consent for participation * No dental infection * No programmed dental surgery during the treatment * Effective contraception for women of childbearing potential * Patient with advanced otosclerosis defined by: * Slowly progressive uni or bilateral hearing loss * No past medical history of chronic otitis media * No past medical history of other causes of cochlear damage (significant surgical trauma with a 30 dB deterioration of bone conduction at 4000 Hz in postoperative period, sound trauma, barotrauma, ototoxic drugs) * Normal tympanic membranes * A conductive or mixed hearing loss * A moderate to severe hearing loss on at least one ear (average of thresholds at 500, 1000, 2000 and 4000 Hz) on air conduction between 30 and 90 dB. * Normal tympanometry or with a decreased peak * Absent ipsilateral stapedial reflex * As possible, intraoperative confirmation of stapediovestibular ankylosis * radiological confirmation if CT-scan before inclusion available
Exclusion criteria
* Individuals not covered by the french public health insurance * Pure-tone average \< 30 dB ou \> 90 dB * Programmed stapes surgery during the observation period * Previous treatment by biphosphonate * Known intolerance to tiludronate * Other contraindications to tiludronate treatment: * allergy to biphosphonates * hypersensitivity to one of the excipients * severe renal failure (creatinine clearance \< 30 mL/min) * juvenile Paget's disease * pregnancy and breastfeeding * galactose intolerance, lactase insufficiency, glucose-galactose malabsorption * Ongoing chemotherapy or radiotherapy or patient achieves of a cancer * Long-term systemic steroid treatment
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Hearing preservation on pure-tone audiometry at 2 years | year 2 | Effect on hearing preservation as assessed by air conduction pure-tone average at 2 years. Hearing deterioration is defined by a deterioration of pure-tone average by air conduction \>20 dB at 500, 1000, 2000 and 4000 Hz between inclusion and the end of the observation period. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| cochlear function | years 1 and 2 | Effect on cochlear function preservation as evaluated by bone conduction pure-tone average (500, 1000, 2000 and 4000 Hz) at 1 and 2 years. |
| Stapedial reflex preservation | years 1 and 2 | Percentage of stapedial reflex preservation on the controlateral ear if unilateral otosclerosis at 1 and 2 years. |
| Speech reception threshold and speech discrimination score | years 1 and 2 | Effect on speech reception threshold ans speech discrimination score at 1 and 2 years. |
| hearing preservation at one year | year 1 | Effect on hearing preservation as assessed by air conduction pure-tone average at 1 year |
| Radiological bone density | year 2 | Effect on radiological bone density at fissula ante fenestram as assessed on high resolution temporal bone CT-scans before and after treatment by calculation of fissula ante fenestram / temporal bone squama cortex bone density ration on axial views. |
| Tolerance | month 3 | Clinical tolerance during treatment |
| Tinnitus and balance disorders | years 1 and 2 | Effect on the prevalence and the intensity of tinnitus and balance disorders as evaluated by questionnary at 1 and 2 years. |
Countries
France
Outcome results
None listed